1 Thirty days
after BNCT, mice bearing TK1(+) L929 tumors had a 15x reductio
2 gliomas, which had received i.t. BSD-EGF
and BNCT, had a MST of 45 +/- 5 days compared with 33 +/- 2
3 of the distribution of a clinically
approved BNCT drug.
4 ty and similar or even superior potential
as BNCT agents compared with different classes of 3CTAs.
5 efficacy of binary cancer therapies such
as BNCT and PDT depends critically on the subcellular local
6 n surgically removed malignant tissue
before BNCT.
7 ly 24 h before BPA administration (ALA +
BPA-
BNCT).
8 ing in improved survival compared to the
BPA-
BNCT group.
9 the sensitivity of malignant gliomas to
BPA-
BNCT.
10 fluence was the limiting factor
controlling BNCT efficacy in this study.
11 therapy approach has been known for
decades,
BNCT failed to reach the daily clinics to date.
12 For BNCT experiments, tumor-bearing mice were irradiated 54
13 ered as a promising boron delivery agent
for BNCT.
14 d transporters, making it an ideal agent
for BNCT.
15 pment of potential boron delivery agents
for BNCT as well as new bioactive compounds containing a neg
16 produce selective boron delivery agents
for BNCT.
17 of high and low molecular weight agents
for BNCT.
18 o not appear to be suitable boron agents
for BNCT.
19 These results are important
for BNCT, because clinical protocols using a 2-h infusion ha
20 make boronated aptamers as therapeutics
for BNCT.
21 d to simulate a continuous infusion used
for BNCT therapy.
22 er diagnosis and can potentially be used
for BNCT.
23 n of tumor growth was observed in mice
given BNCT vs. control mice (only 424% increase in tumor volum
24 n the characteristics of the main
historical BNCT drug 4-borono-l-phenylalanine (BPA).
25 In female mice tumour
models,
BNCT and the controlled drug release triggered by locali
26 rug that has the potential to improve
modern BNCT interventions.
27 ke of BPA and improving the effectiveness
of BNCT.
28 ta are the first to show in vivo efficacy
of BNCT using a high molecular weight boronated bioconjugat
29 potentially enhance the therapeutic ratio
of BNCT by >25%.
30 Also in terms
of BNCT treatment, BA emerges again as an efficient boron c
31 rticular significance for clinical trials
of BNCT for human glioblastoma multiforme using the drug BP
32 , it was possible to extend the follow-up
of BNCT treatment groups to 16 wk after the first treatment
33 prove valuable for patient selection and
pre-
BNCT treatment planning.
34 of the biodistribution of BPA-Fr enables
pre-
BNCT calculation of expected tissue dosimetry for a sele
35 human glioblastoma tissue obtained from
pre-
BNCT surgical biopsy.
36 Once-
repeated BNCT treatment with readministration of liposomes at an
37 Based on these favorable
results,
BNCT studies were then initiated in rats bearing intrace
38 On the basis of these
results,
BNCT was initiated at the Brookhaven National Laboratory
39 Successful BNCT depends on knowledge of the distribution of boron-c
40 tron-activated boron capsule that
synergizes BNCT and controlled immune adjuvants release to provoke
41 quencing unveils the fact and mechanism
that BNCT heats anti-tumour immunity.
42 unds promising boron delivery agents for
the BNCT of brain tumors.
43 Boron neutron capture
therapy (
BNCT) allows the selective elimination of malignant tumo
44 pplication of boron neutron capture
therapy (
BNCT) following liposomal delivery of a (10)B-enriched p
45 Boron neutron capture
therapy (
BNCT) is a high-LET particle radiotherapy clinically tes
46 Boron neutron capture
therapy (
BNCT) is a re-emerging binary cellular level cancer inte
47 Success of boron neutron capture
therapy (
BNCT) is dependent on cellular and molecular targeting o
48 Boron neutron capture
therapy (
BNCT) is dependent on the selective accumulation of boro
49 pplication of boron neutron capture
therapy (
BNCT) mediated by liposomes containing (10)B-enriched po
50 d N5-2OH, for boron neutron capture
therapy (
BNCT) of brain tumors using the RG2 rat glioma model.
51 Boron neutron capture
therapy (
BNCT) using 4-[10B]boronophenylalanine-fructose (BPA-Fr)
52 Boron neutron capture
therapy (
BNCT) was clinically approved in 2020 and exhibits remar
53 Boron neutron capture
therapy (
BNCT), a binary treatment modality that can potentially
54 pplication of boron neutron capture
therapy (
BNCT), a noninvasive approach to eliminate cancer cells.
55 Boron neutron capture
therapy (
BNCT), an experimental treatment for certain cancers, de
56 ry agents for boron neutron capture
therapy (
BNCT).
57 evaluated for boron neutron capture
therapy (
BNCT).
58 This suggests that ALA may sensitize GSCs
to BNCT by upregulating the expression of amino acid transp
59 could sensitize glioma stem cells (GSCs)
to BNCT by enhancing the uptake of BPA.
60 ) is in Phase II clinical trials to
validate BNCT as a treatment for glioblastoma multiforme and mela
61 earing mice at 2-hour intervals, after
which BNCT was carried out at the Massachusetts Institute of T